drugset / Trial / NCT01601093

Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

NCT01601093

Phase 2 Suspended 288 enrolled Xiangbei Welman Pharmaceutical Co., Ltd
RandomizedFactorialSingle-blindTreatment

Summary

In the proposed study, the investigators plan to evaluate the efficacy and safety of Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.

Timeline

Start
2011-11
Primary completion
2022-08-15
Completion
2022-12-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cefoperazone Small molecule 2 g Intravenous
Subject Ceftazidime Small molecule 2 g Intravenous
Subject Ceftazidime Small molecule 3 g Intravenous
Subject Sulbactam Small molecule 1 g Intravenous
Subject Sulbactam Small molecule 1.5 g Intravenous